Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ-MC203
- Development stage
- Preclinical
- Lead developer
- TJ Biopharma
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TJ-MC203 is a preclinical-stage trispecific antibody (TsAb) being developed by TJ Biopharma for the treatment of severe autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (scleroderma). Engineered using TJ Biopharma's proprietary AntibodyPLUS platform, TJ-MC203 is designed to simultaneously target and modulate multiple immune pathways. Its specific molecular targets have not been publicly disclosed.
- Other names
- TJ MC203TJMC203TJMC-203TJMC 203
Beyond the preview
Go deeper on TJ-MC203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ-MC203.